← Eichor
Study identifier: NCT05804643 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Novel MRI Techniques on Evaluation of Lymphedema

Condition: Lymphedema of Upper Limb  ·  Sponsor: National Taiwan University Hospital

PhaseN/A
Planned participants210
Who can joinAll sexes, 20 Years to no upper limit
Healthy volunteersYes

About this study

In this project, the investigators aim to investigate the imaging approaches for breast cancer-related secondary lymphedema. The clinical study aims to optimize the conventional MRI methods for mapping lymphedema and assess the post-surgical therapeutic effects in longitudinal follow-up studies. Additionally, a normal imaging database of lymphedema MRI images will be established for future reference. For pre-clinical animal study, investigators aim to develop and integrate two novel MRI methods, including free water elimination diffusion MRI and diffusion kurtosis MRI techniques. By integrating clinical and pre-clinical studies, the investigators aim to establish a precise imaging tool for evaluating the therapeutic effects of lymphedema for following translational applications.

This description comes directly from the study's public registry record.

Talk to the study team

Yeefan Lee, MD  ·  +886-972653172  ·  yeefanlee@ntu.edu.tw

Always discuss trial participation with your own doctor first.

Locations (1)

National Taiwan university hospitalTaipei, TaiwanRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05804643